|Bid||18.00 x 1200|
|Ask||20.00 x 1000|
|Day's Range||19.00 - 19.86|
|52 Week Range||4.30 - 22.86|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors aim to invest in companies that have high profitability level irrespective of the current market scenario. In this respect, profitability analysis can be used to detect a profitable company from a loss-making one. Here, we have used the concept of accounting ratios to evaluate a company’s profitability.
On July 6, BioLife Solutions (BLFS) stock closed at $17.02, ~508% higher than its 52-week low of $2.80 on July 7, 2017. After BioLife’s July 2 announcement of its Q2 2018 results, its stock rose ~31.38% to $14.99 from $11.41 the day before. On July 3, the stock rose ~11.41% to close at $16.70. Last Friday, BioLife stock rose ~49% week-over-week to $17.02 from $11.41.
On July 2, BioLife Solutions released its preliminary revenue numbers for the second quarter. BioLife Solutions’ management increased its fiscal 2018 revenue guidance to $18.5 million–$20.0 million compared to its prior guidance of $14.5 million–$15.5 million.
BioLife Solutions’ (BLFS) biopreservation portfolio includes: hypothermic storage and cryopreservation freeze media products blood stem cell freezing products custom product formulation and custom packaging services contract aseptic manufacturing formulation, fill and finish of liquid media products Target market
BioLife Solutions (BLFS) is focused on bringing to market clinical grade cell and tissue hypothermic storage and cryopreservation freeze media. Its product platforms cater primarily to the biobanking, drug discovery, and regenerative medicine markets.
BioLife Solutions Inc’s (NASDAQ:BLFS): BioLife Solutions, Inc. develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions for cells and tissues in the United States. The US$77.82M market-cap posted aRead More...
I am going to run you through how I calculated the intrinsic value of BioLife Solutions Inc (NASDAQ:BLFS) using the discounted cash flow (DCF) method. Anyone interested in learning aRead More...
Categories: Yahoo FinanceGet free summary analysis BioLife Solutions, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of BioLife Solutions, Inc. – Evogene Ltd (EVGN-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 2.96 million, Net Earnings of USD -0.32 million. ... Read more (Read more...)
When BioLife Solutions Inc (NASDAQ:BLFS) released its most recent earnings update (30 September 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarksRead More...
The Zacks Analyst Blog Highlights: BioLife Solutions, SeaSpine Holdings, Apollo Endosurgery and CareDx
Zacks.com featured highlights: H&E Equipment Services, Nomad Foods, Strayer Education, BioLife Solutions and Assembly Biosciences
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioLife Solutions, Inc. Here are 5 ETFs with the largest exposure to BLFS-US. Comparing the performance and risk of BioLife Solutions, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)